 Jounce Therapeutics, Inc. JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will now host the Companys 2020 Annual Meeting of Stockholders the Annual Meeting virtually due to the public health impact of the coronavirus COVID-19 pandemic and to prioritize the health and well-being of meeting participants. Stockholders will not be able to attend the Annual Meeting in person. Stockholders are entitled to attend and vote if they were a stockholder as of the close of business on April 28, 2020, the record date, or hold a legal proxy for the meeting provided by the stockholders bank, broker or nominee as of such record date. 